Antithrombotic Therapy in Blunt Cerebrovascular Injury: Associations With In-Hospital Mortality in a Contemporary Trauma Cohort
The American Surgeon™ · 2026-12 · 92 (12) · 3477-3480
DOI: 10.1177/00031348261472857 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Surgeon™, online erschienen am 29.07.2026. Verfasst von Morgan K Schuster und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Hauptthemen laut MEDLINE: Hospital Mortality, Aspirin, Heparin, Low-Molecular-Weight, Fibrinolytic Agents. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
At our institution, aspirin (ASA) is the recommended treatment for blunt cerebrovascular injury (BCVI), and low molecular weight heparin (LMWH) is the preferred agent for venous thromboembolism prophylaxis. While both therapies are widely used and individually safe, evidence regarding their combined use in BCVI patients is limited. This study evaluated the safety of concurrent LMWH and ASA therapy in trauma patients with BCVI. Materials and Methods: We analyzed trauma admissions from 2021-2024 using the institutional trauma registry and an electronic medical record–based data warehouse at an adult Level I trauma center. Patients with and without BCVI were included. Univariate and bivariate analyses were performed using Student’s t-tests and chi-square tests, and multivariable logistic regression assessed associations between BCVI, medication use, and in-hospital mortality.
Results
Among 4,306 included patients, 365 (8.5%) had BCVI. The mean age was 42 years, 36% were female, and 59% were White. After adjustment, BCVI was associated with increased odds of in-hospital mortality (OR 2.03, 95% CI 1.14-3.61, P = 0.015). Among patients with BCVI, treatment with LMWH alone, ASA alone, or combined LMWH and ASA was associated with significantly lower odds of in-hospital death (LMWH OR 0.09; ASA OR 0.29; combination OR 0.20; all P < 0.05).
Discussion
Although BCVI occurred in fewer than one in twelve patients, it was associated with more than double the odds of mortality. Medical therapy, including combined antiplatelet and anticoagulant treatment, appears to be safe for use in BCVI patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- Division of Acute Care Surgery, Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
ORCID-Profile: Morgan K Schuster, Hanna K Jensen, Kyle J Kalkwarf
Zitieren
APA
Schuster, M. K., Jensen, H. K., Bowman, S. M., & Kalkwarf, K. J. (2026). Antithrombotic Therapy in Blunt Cerebrovascular Injury: Associations With In-Hospital Mortality in a Contemporary Trauma Cohort. The American Surgeon™, 92(12), 3477-3480. https://doi.org/10.1177/00031348261472857
Vancouver
Schuster MK, Jensen HK, Bowman SM, Kalkwarf KJ. Antithrombotic Therapy in Blunt Cerebrovascular Injury: Associations With In-Hospital Mortality in a Contemporary Trauma Cohort. The American Surgeon™. 2026;92(12):3477-3480. doi:10.1177/00031348261472857
BibTeX
@article{Schuster2026,
author = {Schuster, Morgan K and Jensen, Hanna K and Bowman, Stephen M and Kalkwarf, Kyle J},
title = {Antithrombotic Therapy in Blunt Cerebrovascular Injury: Associations With In-Hospital Mortality in a Contemporary Trauma Cohort},
journal = {The American Surgeon™},
year = {2026},
volume = {92},
number = {12},
pages = {3477--3480},
doi = {10.1177/00031348261472857}
}
EUVIMED